Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

In this retrospective analysis, dutasteride mesotherapy was used in 10 patients with androgenetic alopecia and resulted in hair density and width changes measured at the scalp, but specific efficacy results are not detailed in the abstract.

This review found limited evidence on the effectiveness of different antiandrogens for feminization in transgender women, suggesting cyproterone acetate, leuprolide, and medroxyprogesterone acetate may better suppress testosterone than spironolactone or estradiol alone.

In this systematic review, researchers found that injectable therapies, including agents like dutasteride and multivitamin formulations, may offer cosmetic benefits for androgenetic alopecia; however, evidence is limited by small study sizes, varied methods, and short follow-up periods, necessitating standardized trials for routine use recommendations.

This paper argues that androgenetic alopecia in transgender and gender-diverse individuals is clinically significant, suggesting individualized and gender-affirming treatment approaches, with oral minoxidil as a key therapy.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

This article reviews treatment options for female-pattern hair loss, noting the limited evidence for most therapies and emphasizing that topical minoxidil remains the only well-supported option despite a significant non-response rate.

This study reported that anti-androgens combined with lifestyle modifications were more effective than metformin and lifestyle in reducing hirsutism and certain hormonal measures in women with PCOS, but they were not more effective than a placebo combined with lifestyle changes.

This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.